SARS-CoV-2: Targeted managements and vaccine development
Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in
diverse outcomes. The symptoms appear to be more severe in males older than 65 and …
diverse outcomes. The symptoms appear to be more severe in males older than 65 and …
[HTML][HTML] Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections
Intravenous immunoglobulins (IVIG) are blood preparations pooled from the plasma of
donors that have been first employed as replacement therapy in immunodeficiency. IVIG …
donors that have been first employed as replacement therapy in immunodeficiency. IVIG …
[HTML][HTML] Convalescent plasma for the prevention and treatment of COVID-19: a systematic review and quantitative analysis
Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2,
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …
has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following …
[HTML][HTML] Efficacy and outcome of remdesivir and tocilizumab combination against dexamethasone for the treatment of severe COVID-19: A randomized controlled trial
ATM Mohiuddin Chowdhury, A Kamal… - Frontiers in …, 2022 - frontiersin.org
Objective: In this study, we investigated the efficacy and safety of remdesivir and tocilizumab
combination therapy against dexamethasone for the management of severe COVID-19 …
combination therapy against dexamethasone for the management of severe COVID-19 …
Convalescent plasma therapy for management of COVID-19: Perspectives and deployment in the current global pandemic
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare
professionals are struggling to treat their patients based on nonspecific therapies. Amidst …
professionals are struggling to treat their patients based on nonspecific therapies. Amidst …
[HTML][HTML] Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review
D Andaluz-Ojeda, P Vidal-Cortes, ÁA Sanz… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic …
causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic …
[HTML][HTML] Convalescent plasma therapy-a silver lining for COVID-19 management?
S Saha, S Kadam - Hematology, transfusion and cell therapy, 2021 - SciELO Brasil
The COVID-19 pandemic has pushed the world towards social, economic, and medical
challenges. Scientific research in medicine is the only means to overcome novel and …
challenges. Scientific research in medicine is the only means to overcome novel and …
Prognosis and the Global Impact of the COVID-19 Pandemic-A Comprehensive Review
Background: The novel coronavirus 2019 or SARS-CoV-2 appeared first in the December,
2019, in the Wuhan, China. The virus later effected almost every part of the world. Aim of the …
2019, in the Wuhan, China. The virus later effected almost every part of the world. Aim of the …
[HTML][HTML] Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection
ED Stea, V Pronzo, F Pesce… - Journal of Clinical …, 2022 - clinnephrologyjournal.com
Endotheliosis, thrombotic microangiopathy and complement system over activation have
been described as pathologic features of tissue damage in the setting of coronavirus …
been described as pathologic features of tissue damage in the setting of coronavirus …
Development of a minicircular DNA vaccine against COVID-19
CL Ventura - 2022 - ubibliorum.ubi.pt
Nucleic acid vaccines have proven to be a promising technology in the fight against global
threats such as coronavirus disease (COVID-19). Minicircle DNA (mcDNA) is an innovative …
threats such as coronavirus disease (COVID-19). Minicircle DNA (mcDNA) is an innovative …